Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTL0018318 in Alzheimer's Disease
NCT03456349Phase 1Completed
- Sponsor
- Nxera Pharma
- Start
- Nov 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of HTL0018318 in Alzheimer's disease (AD) (4 arms), sponsored by Nxera Pharma. Primary endpoint: Treatment Emergent Adverse Events. Started Nov 2017; status: completed.
02
Drugs
HTL0018318
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03456349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03456349.